Makoae Lucy N, Portillo Carmen J, Uys Leana R, Dlamini Priscilla S, Greeff Minrie, Chirwa Maureen, Kohi Thecla W, Naidoo Joanne, Mullan Joseph, Wantland Dean, Durrheim Kevin, Holzemer William L
National University of Lesotho, Lesotho, South Africa.
AIDS Care. 2009 Nov;21(11):1357-62. doi: 10.1080/09540120902862576.
This study examined the impact of taking or not taking antiretroviral (ARV) medications on stigma, as reported by people living with HIV infection in five African countries.
A two group (taking or not taking ARVs) by three (time) repeated measures analysis of variance examined change in reported stigma in a cohort sample of 1454 persons living with HIV infection in Lesotho, Malawi, South Africa, Swaziland, and Tanzania. Participants self-reported taking ARV medications and completed a standardized stigma scale validated in the African context. Data were collected at three points in time, from January 2006 to March 2007. Participants taking ARV medications self-reported a mean CD4 count of 273 and those not taking ARVs self-reported a mean CD4 count of 418.
Both groups reported significant decreases in total HIV stigma over time; however, people taking ARVs reported significantly higher stigma at Time 3 compared to those not taking ARVs.
This study documents that this sample of 1454 HIV infected persons in five countries in Africa reported significantly less HIV stigma over time. In addition, those participants taking ARV medications experienced significantly higher HIV stigma over time compared to those not taking ARVs. This finding contradicts some authors' opinions that when clients enroll in ARV medication treatment it signifies that they are experiencing less stigma. This work provides caution to health care providers to alert clients new to ARV treatment that they may experience more stigma from their families and communities when they learn they are taking ARV medications.
本研究调查了在五个非洲国家感染艾滋病毒的人群中,服用或不服用抗逆转录病毒(ARV)药物对耻辱感的影响。
采用两组(服用或不服用抗逆转录病毒药物)×三次(时间)重复测量方差分析,对莱索托、马拉维、南非、斯威士兰和坦桑尼亚1454名感染艾滋病毒的队列样本中报告的耻辱感变化进行研究。参与者自行报告服用抗逆转录病毒药物的情况,并完成在非洲背景下验证的标准化耻辱感量表。数据在2006年1月至2007年3月的三个时间点收集。服用抗逆转录病毒药物的参与者自行报告的平均CD4细胞计数为273,未服用抗逆转录病毒药物的参与者自行报告的平均CD4细胞计数为418。
两组均报告随着时间推移,艾滋病毒总体耻辱感显著下降;然而,与未服用抗逆转录病毒药物的人相比,服用抗逆转录病毒药物的人在时间3时报告的耻辱感显著更高。
本研究记录了非洲五个国家的这1454名艾滋病毒感染者样本随着时间推移报告的艾滋病毒耻辱感显著减少。此外,与未服用抗逆转录病毒药物的参与者相比,服用抗逆转录病毒药物的参与者随着时间推移经历的艾滋病毒耻辱感显著更高。这一发现与一些作者的观点相矛盾,即当患者开始接受抗逆转录病毒药物治疗时,表明他们遭受的耻辱感较少。这项研究提醒医疗保健提供者,要告知刚开始接受抗逆转录病毒治疗的患者,当他们的家人和社区得知他们正在服用抗逆转录病毒药物时,他们可能会遭受更多的耻辱感。